Survival of HIV-infected patients after starting tuberculosis treatment: a prospective cohort study

被引:19
作者
Maruza, M. [1 ]
Albuquerque, M. F. P. M. [2 ]
Braga, M. C. [2 ]
Barbosa, M. T. S. [3 ]
Byington, R. [4 ]
Coimbra, I. [1 ]
Moura, L. V. [1 ]
Batista, J. D. L. [2 ]
Diniz, G. T. N. [2 ]
Miranda-Filho, D. B. [1 ]
Lacerda, H. R. [1 ]
Rodrigues, L. C. [5 ]
Ximenes, R. A. A. [1 ]
机构
[1] Univ Fed Pernambuco, Recife, PE, Brazil
[2] Fundacao Oswaldo Cruz, Ctr Pesquisas Aggeu Magalhaes, Recife, PE, Brazil
[3] Univ Estado Rio De Janeiro, Rio De Janeiro, Brazil
[4] Inst Nacl Canc, Rio De Janeiro, Brazil
[5] London Sch Hyg & Trop Med, London WC1, England
关键词
AIDS; risk; death; ACTIVE ANTIRETROVIRAL THERAPY; RISK-FACTORS; MORTALITY; DEATH; PREDICTORS; ANEMIA; ERA;
D O I
10.5588/ijtld.11.0110
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
OBJECTIVES: To estimate the probability of survival and to evaluate risk factors for death in a cohort of persons living with human immunodeficiency virus (PLHIV) who had started tuberculosis (TB) treatment. METHODS: A prospective cohort study was conducted between June 2007 and December 2009 with HIV-infected patients who had started anti-tuberculosis treatment in the State of Pernambuco, Brazil. Survival data were analysed using the Kaplan-Meier estimator, the log-rank test and the Cox model. Hazard ratios and their respective 95%CIs were estimated. RESULTS: Of a cohort of 2310 HIV-positive individuals, 333 patients who had commenced treatment for TB were analysed. The mortality rate was 5.25 per 10 000 person-years (95%CI 4.15-6.63). The probability of survival at 30 months was 74%. Risk factors for death in the study population were being female, age >= 30 years, having anaemia, not using highly active antiretroviral therapy (HAART) during treatment for TB and disseminated TB. Protective factors for death were a CD4 lymphocyte count >200 cells/mm(3) and treatment for TB having started in an out-patient clinic. CONCLUSIONS: The use of HAART can prevent deaths among HIV-TB patients, corroborating the efficacy of starting HAART early in individuals with TB.
引用
收藏
页码:618 / 624
页数:7
相关论文
共 36 条
[1]   RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE [J].
ACKAH, AN ;
COULIBALY, D ;
DIGBEU, H ;
DIALLO, K ;
VETTER, KM ;
COULIBALY, IM ;
GREENBERG, AE ;
DECOCK, KM .
LANCET, 1995, 345 (8950) :607-610
[2]  
Aerts D, 2004, INT J TUBERC LUNG D, V8, P785
[3]   Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand [J].
Akksilp, Somsak ;
Karnkawinpong, Opart ;
Wattanaamornkiat, Wanpen ;
Viriyakitja, Daranee ;
Monkongdee, Patarna ;
Sitti, Walya ;
Rienthong, Dhanida ;
Siraprapasiri, Taweesap ;
Wells, Charles D. ;
Tappero, Jordan W. ;
Varma, Jay K. .
EMERGING INFECTIOUS DISEASES, 2007, 13 (07) :1001-1007
[4]  
[Anonymous], 2008 REP GLOB AIDS E
[5]   Treatment strategies for HIV-infected patients with tuberculosis: Ongoing and planned clinical trials [J].
Blanc, Francois-Xavier ;
Havlir, Diane V. ;
Onyebujoh, Philip C. ;
Thim, Sok ;
Goldfeld, Anne E. ;
Delfraissy, Jean-Francois .
JOURNAL OF INFECTIOUS DISEASES, 2007, 196 :S46-S51
[6]   Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy [J].
Breen, RAM ;
Miller, RF ;
Gorsuch, T ;
Smith, CJ ;
Ainsworth, J ;
Ballinger, J ;
Swaden, L ;
Cropley, I ;
Johnson, MA ;
Lipman, MCI .
JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (10) :1437-1440
[7]  
Català L, 2011, INT J TUBERC LUNG D, V15, P263
[8]  
Ciglenecki I, 2007, INT J TUBERC LUNG D, V11, P1121
[9]   Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy [J].
Dheda, K ;
Lampe, FC ;
Johnson, MA ;
Lipman, MC .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (09) :1670-1676
[10]  
Fangman John J W, 2005, Curr Hematol Rep, V4, P95